tbuckley/cabot-search huggingface dataset:
THU0351 Vitamin D Insufficency Is Associated To Fatigue in Non-Supplemented Women with Systemic Lupus Erythematosus in A Mediterranean Region:
Authors: T.C. Salman-Monte, P. Corzo, F. Castro, L. Polino, V. Torrente-Segarra, J. Carbonell-Abello
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> It has been previously reported that vitamin D deficiency is more prevalent among SLE patients than in the general population. We sought to determine the prevalence of vitamin D insufficiency and deficiency and their related factors, its relationship to SLE symptoms and disease activity on a group of supplemented and non-supplemented female SLE patients from the Mediterranean region. <h3>Methods</h3> We performed a cross-sectional study including female SLE patients who regularly attended the outpatient Lupus Unit at Parc de Salut Mar-IMAS in Barcelona, from January 2012 and May 2014. Collected data were: sociodemographics; vitamin D supplementation; fatigue degree visual analog scale; pharmacological treatment; main SLE serological markers, Indexes, scales; and plasma levels of 25-hydroxy vitamin D <h3>Results</h3> One-hundred and two consecutive female SLE patients were included. Vitamin D overall insufficiency and deficiency were exhibited by 46% and 22.5% of patients, respectively. Vitamin D insufficiency was found in 50% of supplemented and 60% of non-supplemented patients. Among non-supplemented female SLE patients, it was found that patients with Vitamin D insufficiency showed more fatigue (p=0.009) and received more oral corticosteroids (p=0.02) than those with normal levels. Patients with Vitamin D insufficiency (supplemented and non-supplemented) received more oral corticosteroids than those without insufficiency (p=0.008). <h3>Conclusions</h3> Vitamin D insufficiency is highly prevalent among female SLE patients, even in southern regions. Non-supplemented female SLE patients showed more fatigue and received more oral corticosteroids than those with normal levels of Vitamin D. This data was not found in supplemented patients despite having a high prevalence of Vitamin D insufficiency (up to 50%). Further studies with longer follow-up and larger population are needed to confirm our observations. <h3>Disclosure of Interest</h3> None declared
AB0735 The Annual Incidence of Newly Diagnosed Psoriatic Arthritis in Russian Patients with Psoriasis Is Suspected To Be Higher than Officials Report: A Population-Based Study
Authors: M. Olesya, K. Tatyana, S. Vladimir, N. Evgeniy
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Psoriatic arthritis (PsA) occurs in 6.2–42% of patients (pts) with psoriasis (PsO). The results range widely among different populations due to some difficulties in performing epidemiological studies, heterogeneous clinical presentations of PsA, and the lack of world accepted criteria and questionnaires and low awareness of the risk PsA in PsO pts among dermatologists. <h3>Objectives</h3> to estimate the mean annual incidence of PsA in Russian pts with PsO according to medical statistics record and to compare with direct interview results of pts with PsO in dermatologic clinics across Russian Federation. <h3>Methods</h3> Analysis of the number of newly diagnosed PsA among the adult and children above 14 years Russian pts with PsO coding in official medical records as L40.5+ by International Statistical Classification of Disease and Related Health Problems (ICD-10) between 2009 - 2013 years. 1091 pts with different clinical types of PsO at the same age were called to the dermatological offices to be direct interviewed by dermatologists and responded to follow questions: Do you have any joint pain? Do you have PsA confirmed by rheumatologists? The mean annual incidence of PsA in PsO pts were calculated by formula. <h3>Results</h3> Between 2009 - 2013 the mean annual incidence of newly diagnosed PsA in Russian pts with PsO estimated at 2.5% or 1.9/100.000 cases for whole Russian population. Among 1091 interviewed PsO pts in dermatologic offices 27.9% of pts have joint complaints and 8% of pts have PsA confirmed by rheumatologists. <h3>Conclusions</h3> The mean annual incidence of PsA in the Russian pts with PsO is lower than reported before in other populations due to under diagnosis, heterogeneous clinical presentations of PsA and coding problems in dermatological clinics. Iinterdisciplinary collaboration with rheumatologists is needed. <h3>Disclosure of Interest</h3> None declared
Myc-Directed Suppression of Autophagy Provides Therapeutic Vulnerabilities Targeting Amino Acid Homeostasis
Authors: Franz X Schaub, Weimin Li, Mohammad Fallahi, Chunying Yang, Stephanie K Schaub, Soyoung Lee, Alexandar Tzankov, Clemens Schmitt, Antonio L Amelio, John L. Cleveland
Journal: Blood (2015)
MiR-181b in Chronic Lymphocytic Leukemia B Cells Is Regulated By Cellular Interaction with CD4+ T Cells and Increases the CTL Toxicity Versus the Leukemic Clone
Authors: Mirco di Marco, Serena Veschi, Rosa Visone, Giuseppe Leone, Paola Lanuti, Sara Pagotto, Felice Pepe, Stefania Pacillo, Claudia Curcio, Marco Marchisio, Sebastiano Miscia, Idanna Innocenti, Francesco Autore, Barbara Vannata, Mario Di Gioacchino, Renato Mariani-Costantini, Luca Laurenti, Angelo Veronese
Journal: Blood (2015)
Arthroscopic surgery for knee pain: a highly questionable practice without supporting evidence of even moderate quality
Authors: Teppo L N Järvinen, Gordon H Guyatt
Journal: British Journal of Sports Medicine (2016)

With 150 000 knee arthroscopies carried out in the United Kingdom each year, and about five times that number in the United States,1 ,2 arthroscopic partial meniscectomy—keyhole surgery for middle aged to older adults with knee pain to trim a torn meniscus—is one of the most common surgical procedures. Considering the enormous volume, it is natural to think that there is compelling evidence for the procedure being beneficial. Remarkably, this is not so.

It is barely a decade since the publication of the first controlled trial addressing knee arthroscopy using placebo surgery as a comparator.3 Since then a series of rigorous trials, summarised in two recent systematic reviews and meta-analyses, provide compelling evidence that arthroscopic knee surgery offers little benefit for most patients with knee pain.4 ,5 The latest nail into what should be …
Cancer somatic mutations cluster in a subset of regulatory sites predicted from the ENCODE data
Authors: Nisar A. Shar, M. S. Vijayabaskar, David R. Westhead
Journal: Molecular Cancer (2016)

Transcriptional regulation of gene expression is essential for cellular differentiation and function, and defects in the process are associated with cancer. The ENCODE project has mapped potential regulatory sites across the complete genome in many cell types, and these regions have been shown to harbour many of the somatic mutations that occur in cancer cells, suggesting that their effects may drive cancer initiation and development. The ENCODE data suggests a very large number of regulatory sites, and methods are needed to identify those that are most relevant and to connect them to the genes that they control. Predictive models of gene expression were developed by integrating the ENCODE data for regulation, including transcription factor binding and DNase1 hypersensitivity, with RNA-seq data for gene expression. A penalized regression method was used to identify the most predictive potential regulatory sites for each transcript. Known cancer somatic mutations from the COSMIC database were mapped to potential regulatory sites, and we examined differences in the mapping frequencies associated with sites chosen in regulatory models and other (rejected) sites. The effects of potential confounders, for example replication timing, were considered. Cancer somatic mutations preferentially occupy those regulatory regions chosen in our models as most predictive of gene expression. Our methods have identified a significantly reduced set of regulatory sites that are enriched in cancer somatic mutations and are more predictive of gene expression. This has significance for the mechanistic interpretation of cancer mutations, and the understanding of genetic regulation.
Fibroblast Growth Factor Receptor-1 Expression and Signaling in Acute Myeloid Leukemia.
Authors: Matthias A. Karajannis, Loïc Vincent, Fan Zhang, Sergey V. Shmelkov, Joseph Cheung, Peter Bohlen, Zhenping Zhu, Paul Kussie, Haijun Sun, Shahin Rafii
Journal: Blood (2004)
Targeted Re-Sequencing Analysis of 31 Genes Commonly Mutated in Myeloid Disorders in Serial Samples from Myelodysplastic Syndrome Patients with Disease Progression
Authors: Andrea Pellagatti, Cristina Di Genua, Swagata Roy, Adam Burns, Kathy L McGraw, Maria José Larrayoz, Marta Fernandez-Mercado, Simona Valletta, Joanne Mason, Sally Killick, Cristina Mecucci, Maria José Calasanz, Alan F. List, Anna Schuh, Jacqueline Boultwood
Journal: Blood (2014)
Bortezomib Protects Osteoblasts from Glucocorticoid-Induced Damage, and Enhances Glucocorticoid-Induced Toxicity Against Osteoclasts and Myeloma Cells.
Authors: Kent Soe, Thomas L. Andersen, Katarzyna Kupisiewicz, Torben Plesner, Jean-Marie Delaisse
Journal: Blood (2007)
Premedication with simethicone and N-acetylcysteine in improving visibility during upper endoscopy: a double-blind randomized trial
Authors: Luís Elvas, Miguel Areia, Daniel Brito, Susana Alves, Sandra Saraiva, Ana Cadime
Journal: Endoscopy (2016)

<b>Background and study aim</b> Upper endoscopy is the most common method for the diagnosis of upper gastrointestinal tract diseases. The aim of this study was to determine whether premedication with simethicone or <i>N</i>-acetylcysteine improves mucosal visualization during upper endoscopy. <b>Patients and methods</b> This was a randomized, double-blind, placebo-controlled study of 297 patients scheduled for upper endoscopy who were premedicated 15 – 30 minutes before the procedure with: 100 mL of water (placebo, group A); water plus 100 mg simethicone (group B); water plus 100 mg simethicone plus 600 mg <i>N</i>-acetylcysteine (group C). The primary outcome measure was the quality of mucosal visualization (score: excellent, adequate or inadequate). <b>Results</b> The addition of simethicone (group B) or simethicone plus <i>N</i>-acetylcysteine to the water (group C) improved the visualization scores of endoscopies compared with water alone (group A). In particular, groups B and C produced a significantly higher percentage of endoscopies with excellent visualization for the esophagus (91.1 % and 86.7 %, respectively, vs. 71.4 % in group A; <i>P</i> < 0.001) and stomach (76.2 % and 74.5 % vs. 38.8 % in group A; <i>P</i> < 0.001). For the duodenum, the use of simethicone also showed an increase in the endoscopies with excellent visualization compared with water alone (85.1 % vs. 73.5 %; <i>P</i> = 0.042). There were no significant differences in scores between groups B and C or between gastric scores in patients with previous subtotal gastrectomy (B and C vs. A): 60.0 % and 42.1 % vs. 28.6 % (<i>P</i> = 0.14). The rate of reported lesions was higher in group B but without statistical significance. <b>Conclusions</b> Premedication with simethicone resulted in better mucosal visibility. Such premedication might improve diagnostic yield, and should be considered for standard practice. Trial registered at ClinicalTrials.gov (NCT02357303).
Outcome of two patients harboring EML4-ALK fusion gene with brain metastasis treated with crizotinib
Authors: Tamio Okimoto, Yukari Tsubata, Mika Nakao, Naoya Koba, Takamasa Hotta, Megumi Hamaguchi, Shunnichi Hamaguchi, Akihisa Sutani, Akinobu Hamada, Takeshi Isobe
Journal: Annals of Oncology (2015)
P0159 : Non invasive blood flow measurement by “arterial spin labeling” detects minimal hepatic encephalopathy
Authors: A. Urios, C. Gímenez-Gascó, A. Agustí, A. Mangas-Losadas, R. Garcia, A. Escudero-Sanchis, D. Escudero-García, O. González, M.A. Serra, R. Giner-Durán, V. Belloch, V. Felipo, C. Montoliu
Journal: Journal of Hepatology (2015)
Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial
Authors: Christoph Röllig, Carsten Müller-Tidow, Andreas Hüttmann, Volker Kunzmann, Claudia D Baldus, Christian H. Brandts, Alwin Krämer, Kerstin Schäfer-Eckart, Andreas Neubauer, Stefan W. Krause, Utz Krug, Aristoteles Giagounidis, Walter E. Aulitzky, Martin Bornhäuser, Markus Schaich, Stefani Parmentier, Christian Thiede, Malte von Bonin, Thomas Illmer, Johannes Schetelig, Michael Kramer, Hubert Serve, Wolfgang E Berdel, Gerhard Ehninger
Journal: Blood (2012)
SAT0257 Update on The Juvenile Systemic Sclerosis Inception Cohort Project. Characteristics of The First 74 Patients at First Assessment
Authors: I. Foeldvari, J. Klotsche, O. Kasapcopur, A. Adrovic, M.T. Terreri, V. Stanevicha, M.M. Katsikas, E. Alexeeva, F. Sztajnbok, R. Cimaz, M. Kostik, W.A. Sifuentes-Giraldo, T. Lehman, D. Nemcova, M. Moll, M.J. Santos, T. Avcin, C. Battagliotti, J. Brunner, S. Nielsen, T. Kallinich, K. Minden, M. Janarthanan, L. Harel, Y. Uziel, D. Eleftheriou, K.S. Torok, N. Helmus
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Juvenile systemic sclerosis (jSSc) is an orphan autoimmune disease. Currently just retrospective data exist regarding evolvement of organ involvement. In the retrospective studies assessment of the organ involvement is not standardized. Our project is the first one, where prospectively and with a standardized assessment data of jSSc patients are collected. <h3>Objectives</h3> to learn about the characteristics and evolvement of jSSc <h3>Methods</h3> Patients with jSSc were recruited worldwide and were prospectively assessed, using the proposed standardized patient assessment protocol. <h3>Results</h3> 26 centers from 17 countries applied to participate on the project. The assent and consent forms were translated into the local native languages. Up till now 74 patients were enrolled. Sixty (81%) of the 74 patients were female. The mean age of the onset of Raynaud symptomatic was 9.2 years (0.2 – 15.9). The mean age at the onset of the non-Raynaud symptomatic were 9,7 years (0.3 -15.9). 56 (76%) of the 74 have diffuse subtype, 10 (14%) of them have an overlap symptomatic. At the time of the inclusion the mean modified Rodnan Skin Score was 16.0. ANA positive were 55/71 (77%), 24/70 (34%) of them were anti-Scl 70 positive and 3/42 (7%) was anticentromere positive. 43/74 (58%) had already capillary changes and 36/72 (50%) inactive ulcerations, 13/72 (18%) had active ulceration at the time of the inclusion. 38/74 (51%) had cardiopulmonary involvement, 19/38 (50%) of had signs of interstitial lung disease on imaging, 18/42 (43%) had FVC &lt;80% and 12/21 (57%) had DLCO &lt;80%. 6/38 (16%) patients had pulmonary hypertension. 5/74 (7%) had renal involvement. 26/74 (35%) had gastrointestinal involvement, and 23/26 (88%) of them esophageal involvement. 46/73 (63%) had musculoskeletal involvement. 2/74 (3%) showed neurologic involvement. The mean CHAQ score was 0.4 (0–2.5). Patient global disease activity on VAS (0–100) was 44.9 and disease damage 41.6. Physician global of disease activity on VAS (0–100) was 39.7 and physician global of disease damage was 34.6. <h3>Conclusions</h3> The current recruitment data confirms that pediatric patients are different from the adult patients, there is a significantly higher proportion of diffuse subset patients with 81%. 14% of the patients have overlap features. <h3>Disclosure of Interest</h3> None declared
Association of Treatment with Sirolimus (SIR) and Calcineurin Inhibitor (CNI) for Prevention or Treatment of Graft-Vs-Host Disease (GVHD) with Transplant Associated Microangiopathy (TAM).
Authors: Joseph Rosenthal, Ellen Bolotin, Anna Pawlowska, Cheryl Oliver, Sean Maroongroge, Stephen Forman
Journal: Blood (2008)
Autologous HSCT Induce a Sustained Inhibition of New MRI Lesions in Severe Refractory Multiple Sclerosis. Long Term Results of a Prospective Multicenter Trial.
Authors: Riccardo Saccardi, Massimo Filippi, Maria Pia Sormani, Massimo Di Gioia, Alberto Bosi, Paolo Di Bartolomeo, Amedea Donelli, Francesca Gualandi, Angelo Guerrasio, Giorgio La Nasa, Pietro Maggi, Alberto Marmont, Federico Papineschi, Luisa Vuolo, Maria Annunziata Rocca, Gian Luigi Mancardi
Journal: Blood (2009)
Occupational pesticide exposure and respiratory health: a large-scale cross-sectional study in three commercial farming systems in Ethiopia
Authors: Beyene Negatu, Hans Kromhout, Yalemtshay Mekonnen, Roel Vermeulen
Journal: Thorax (2016)

<h3>Rationale</h3> In the last decade, due to expansion of greenhouses and irrigated farms, the use of pesticides in Ethiopia has increased 6–13-fold leading to potential health risks. <h3>Objective</h3> To investigate if occupational exposure to pesticides is associated with respiratory health effects in farmers and farm workers from commercial farming systems. <h3>Methods</h3> We performed two cross-sectional surveys comprising different farming systems. In the first survey we studied respiratory symptoms among 1104 subjects of which 601 were occupationally exposed to pesticides (ie, 256 pesticide applicators, 345 re-entry workers) and 503 unexposed individuals. The second survey, carried out 2 years later in the same farming regions, additionally included lung function measurement and comprised a total of 387 study subjects of which 206 were occupationally exposed to pesticides (142 applicators and 64 re-entry workers) and 180 unexposed individuals. <h3>Results</h3> We observed increased risks for chronic cough and shortness of breath (OR=3.15, 95% CI 1.56 to 6.36 and OR=6.67, 95% CI 2.60 to 17.58) among the exposed subjects as compared with unexposed individuals in the first survey. These results were corroborated in the second survey where we also observed reductions in FEV<sub>1</sub> (140 mL), forced expiratory flow 25%–75% (550 mL/s) and risk of FEV<sub>1</sub>/FVC ratio &lt;0.8 (OR=4.31, 95% CI 2.11 to 8.81) among pesticide exposed workers. <h3>Conclusions</h3> These findings indicate an increased risk of adverse respiratory health among workers exposed to pesticides. As those effects occurred in young workers (mean age 27 years) and within a relative short duration of exposure (4 years) implementation of stringent occupational health measures are warranted.
T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors
Authors: Teresa Manzo, Tabea Sturmheit, Veronica Basso, Elisabetta Petrozziello, Rodrigo Hess Michelini, Michela Riba, Massimo Freschi, Angela R. Elia, Matteo Grioni, Flavio Curnis, Maria Pia Protti, Ton N. Schumacher, Reno Debets, Melody A. Swartz, Angelo Corti, Matteo Bellone, Anna Mondino
Journal: Cancer Research (2016)

Donor-derived allogeneic T cells evoke potent graft versus tumor (GVT) effects likely due to the simultaneous recognition of tumor-specific and host-restricted minor histocompatibility (H) antigens. Here we investigated whether such effects could be reproduced in autologous settings by TCR gene-engineered lymphocytes. We report that T cells redirected either to a broadly expressed Y-encoded minor H antigen or to a tumor-associated antigen, although poorly effective if individually transferred, when simultaneously administered enabled acute autochthonous tumor debulking and resulted in durable clinical remission. Y-redirected T cells proved hyporesponsive in peripheral lymphoid organs, whereas they retained effector function at the tumor site, where in synergy with tumor-redirected lymphocytes, they instructed TNFα expression, endothelial cell activation, and intratumoral T-cell infiltration. While neutralizing TNFα hindered GVT effects by the combined T-cell infusion, a single injection of picogram amounts of NGR-TNF, a tumor vessel-targeted TNFα derivative currently in phase III clinical trials, substituted for Y-redirected cells and enabled tumor debulking by tumor-redirected lymphocytes. Together, our results provide new mechanistic insights into allogeneic GVT, validate the importance of targeting the tumor and its associated stroma, and prove the potency of a novel combined approach suitable for immediate clinical implementation. Cancer Res; 77(3); 658-71. ©2016 AACR.
AB0670 Ankylosing Spondylitis (AS-P) Patient Centred Education Program Improves Disease Activity and Quality of Life up To 12 Months
Authors: C.A. Inderjeeth, W. Raymond, C. Connor, J. Edelman, N. Cook, K. Briffa, J. McQuade
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patient centered education interventions are rare. After a needs assessment, focus group consultation, and execution of a <i>Plan, Do, Study, Act</i> (PDSA) model, we developed and delivered a multidimensional <i>Ankylosing Spondylitis Education Program</i> (AS-P) to patients referred via a rheumatologist (meeting the New York criteria for AS). <h3>Objectives</h3> To examine the benefits of AS-P for people with Ankylosing Spondylitis (AS) in regards to health status, quality of life and disease activity. <h3>Methods</h3> 79 people were recruited in the intervention. Exclusion criteria: &lt;18yo; non-English speaking; comorbid inflammatory musculoskeletal disease; and/or visual, auditory, or cognitive impairment. Participants attended a weekly 2.5 hour patient centered education session facilitated by same two health professionals over 6 weeks. The scripted content included multidimensional strategies including stretches; self-efficacy and self-management constructs and optional 7th week supervised exercise class. Data collection included demographic, AS disease management characteristics, medication patterns, and outcomes, measured at baseline, 6 weeks, 3 months, 6 months and 12 months using GLM repeated measures ANOVA. Additional outcomes included the: BAS-G, BASDAI, AS-Qol, BASFI, back pain (VAS), PDGA, anxiety (HADs), health distress (HDQ), quality of life (EASIQol), perceived health (GPH), pain (PSEQ), MAFs and SF-36. <h3>Results</h3> At baseline, 43.3% were male and the mean age was 43.5 ±14.5 years. The median time to AS diagnosis from the index symptom experience was 4 years IQR (1–11). The only significant change in medication usage occurred between Month 3 to Month 6 (p=0.018). The BAS-G, BASDAI and the AS-QoL had improved between baseline to 3, 6 and 12 months (all p&lt;0.05). Nocturnal and total back pain had improved between baseline and 12 months (all p&lt;0.05). The PDGA and HDQ had improved between baseline and 12 months (all p&lt;0.05). The EASI-QOL (physical health composite) had improved at 3 and 12 months (p&lt;0.05). There was also a positive trend in the EASIQOL disease activity, emotional state and social composite scores (p&gt;0.05). MAFs demonstrated a sustained improvement over 12 months (p=0.011). Similarly, the SF-36 physical (p=0.001) and mental (p=0.002) composite scores had improved 12 months post-intervention. BASFI (p=0.271) and HADs (p=0.086) demonstrated no improvement 12 months post-intervention. <h3>Conclusions</h3> AS-P for AS is effective in improving AS specific disease activity, pain and QOL scores for up to 12 months. <h3>References</h3> Von Korff, M et al (2002) Organising care for chronic illness. BMJ 325: 92–94. Zochling, J (2011) Measures of symptoms and disease status in ankylosing spondylitis. Arthritis Care &amp; Research 63: S47-S58. <h3>Disclosure of Interest</h3> None declared
Utility of Voriconazole Monitoring and Factors Affecting Its Levels in Patients Undergoing Hematopoietic Stem Cell Transplantation. Single Center Experience From India.
Authors: Gautam Goyal, Vikram Gota, Pravin Patil, Dileep Kumar Achuta, Libin Mathew, Bhausaheb Bagal, Jayant Gawande, Sadhna Kannan, Navin Khattry
Journal: Blood (2012)